Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
Phase 2
3 (100.0%)A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: mFOLFIRINOX
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 455
- Registration Number
- NCT06079346
- Locations
- πΊπΈ
Karmanos Cancer Center, Detroit, Michigan, United States
πΊπΈBaylor College of Medicine, Houston, Texas, United States
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05425576
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Oncotelic Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04801017
- Locations
- π§π·
Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil
News
No news found